Division of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Department of Medicine, Harbor-UCLA Medical Center, Graduate Medical Education, Torrance, CA, USA.
J Dermatolog Treat. 2021 Jun;32(4):473-475. doi: 10.1080/09546634.2019.1670779. Epub 2019 Sep 26.
Isotretinoin has been used off-label in hidradenitis suppurativa (HS) patients with variable results, making it difficult to predict which patients with HS are likely to benefit.
We conducted a retrospective review of HS patients who presented to UCLA HS clinic between August 2009 and March 2018 and collected data on their demographics, reported history of isotretinoin treatment for HS, and treatment response. A number of patient variables were analyzed between the responders and non-responders to see if any were associated with a higher likelihood of a beneficial response.
Of the 209 patients, 39 (18.7%) reported prior treatment with isotretinoin. A beneficial response to isotretinoin was reported by 14 (35.9%) patients, while 25 (64.1%) patients reported no response. When comparing responders to non-responders, responders were more likely to have a history of pilonidal cyst ( = .024). Having a concomitant history of regular or cystic acne did not appear to enhance HS treatment response to isotretinoin.
Our data suggest that for HS patients, having a history of pilonidal cyst is associated with a beneficial response to isotretinoin.
异维 A 酸已被用于治疗化脓性汗腺炎（HS）患者的适应证外用药，但其疗效不一，因此难以预测哪些 HS 患者可能从中受益。
我们对 2009 年 8 月至 2018 年 3 月期间在加利福尼亚大学洛杉矶分校 HS 诊所就诊的 HS 患者进行了回顾性研究，收集了他们的人口统计学数据、报告的异维 A 酸治疗 HS 的病史和治疗反应。分析了 responder 和 non-responder 两组患者之间的多项患者变量，以确定是否有任何变量与更高的获益反应可能性相关。
在 209 名患者中，有 39 名（18.7%）报告曾接受过异维 A 酸治疗。14 名（35.9%）患者报告异维 A 酸治疗有效，而 25 名（64.1%）患者报告无反应。将 responder 与 non-responder 进行比较，发现 responder 更有可能有藏毛窦病史（P =.024）。同时患有寻常性或囊性痤疮的病史似乎并不能增强异维 A 酸治疗 HS 的反应。
我们的数据表明，对于 HS 患者，有藏毛窦病史与异维 A 酸治疗的获益反应相关。
